Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Identifieur interne : 000285 ( Main/Exploration ); précédent : 000284; suivant : 000286Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
Auteurs : Hidayat Hussain [Allemagne] ; Ivan R. Green [Afrique du Sud] ; Ghulam Abbas ; Sergazy M. Adekenov [Kazakhstan] ; Wahid Hussain [Pakistan] ; Iftikhar Ali [Pakistan, République populaire de Chine]Source :
- Expert opinion on therapeutic patents [ 1744-7674 ] ; 2019.
Descripteurs français
- KwdFr :
- Antienzymes (pharmacologie), Antigènes CD (métabolisme), Brevets comme sujet (MeSH), Conception de médicament (MeSH), Diabète de type 2 (enzymologie), Diabète de type 2 (traitement médicamenteux), Découverte de médicament (méthodes), Humains (MeSH), Hypoglycémiants (pharmacologie), Protein Tyrosine Phosphatase, Non-Receptor Type 1 (antagonistes et inhibiteurs), Protein Tyrosine Phosphatase, Non-Receptor Type 1 (métabolisme), Récepteur à l'insuline (métabolisme).
- MESH :
- antagonistes et inhibiteurs : Protein Tyrosine Phosphatase, Non-Receptor Type 1.
- enzymologie : Diabète de type 2.
- métabolisme : Antigènes CD, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Récepteur à l'insuline.
- méthodes : Découverte de médicament.
- pharmacologie : Antienzymes, Hypoglycémiants.
- traitement médicamenteux : Diabète de type 2.
- Brevets comme sujet, Conception de médicament, Humains.
English descriptors
- KwdEn :
- Antigens, CD (metabolism), Diabetes Mellitus, Type 2 (drug therapy), Diabetes Mellitus, Type 2 (enzymology), Drug Design (MeSH), Drug Discovery (methods), Enzyme Inhibitors (pharmacology), Humans (MeSH), Hypoglycemic Agents (pharmacology), Patents as Topic (MeSH), Protein Tyrosine Phosphatase, Non-Receptor Type 1 (antagonists & inhibitors), Protein Tyrosine Phosphatase, Non-Receptor Type 1 (metabolism), Receptor, Insulin (metabolism).
- MESH :
- chemical , antagonists & inhibitors : Protein Tyrosine Phosphatase, Non-Receptor Type 1.
- chemical , metabolism : Antigens, CD, Protein Tyrosine Phosphatase, Non-Receptor Type 1, Receptor, Insulin.
- drug therapy : Diabetes Mellitus, Type 2.
- enzymology : Diabetes Mellitus, Type 2.
- methods : Drug Discovery.
- chemical , pharmacology : Enzyme Inhibitors, Hypoglycemic Agents.
- Drug Design, Humans, Patents as Topic.
Abstract
Introduction: Protein tyrosine phosphatase 1B (PTP1B) inhibition has been recommended as a crucial strategy to enhance insulin sensitivity in various cells and this fact is supported by human genetic data. PTP1B inhibitors improve the sensitivity of the insulin receptor and have the ability to cure insulin resistance-related diseases. In the latter years, targeting PTP1B inhibitors is being considered an attractive target to treat T2DM and therefore libraries of PTP1B inhibitors are being suggested as potent antidiabetic drugs. Areas covered: This review provides an overview of published patents from January 2015 to December 2018. The review describes the effectiveness of potent PTP1B inhibitors as pharmaceutical agents to treat type 2 diabetes. Expert opinion: Enormous developments have been made in PTP1B drug discovery which describes progress in natural products, synthetic heterocyclic scaffolds or heterocyclic hybrid compounds. Various protocols are being followed to boost the pharmacological effects of PTP1B inhibitors. Moreover these new advancements suggest that it is possible to get small-molecule PTP1B inhibitors with the required potency and selectivity. Furthermore, future endevours via an integrated strategy of using medicinal chemistry and structural biology will hopefully result in potent and selective PTP1B inhibitors as well as safer and more effective orally available drugs.
DOI: 10.1080/13543776.2019.1655542
PubMed: 31402706
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).</title><author><name sortKey="Hussain, Hidayat" sort="Hussain, Hidayat" uniqKey="Hussain H" first="Hidayat" last="Hussain">Hidayat Hussain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry , Weinberg 3, D-06120 Halle (Saale) , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry , Weinberg 3, D-06120 Halle (Saale) </wicri:regionArea><wicri:noRegion>06120 Halle (Saale) </wicri:noRegion><wicri:noRegion>06120 Halle (Saale) </wicri:noRegion><wicri:noRegion>D-06120 Halle (Saale) </wicri:noRegion></affiliation></author><author><name sortKey="Green, Ivan R" sort="Green, Ivan R" uniqKey="Green I" first="Ivan R" last="Green">Ivan R. Green</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry and Polymer Science, University of Stellenbosch , Matieland , Stellenbosch , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Chemistry and Polymer Science, University of Stellenbosch , Matieland , Stellenbosch </wicri:regionArea><wicri:noRegion>Stellenbosch </wicri:noRegion></affiliation></author><author><name sortKey="Abbas, Ghulam" sort="Abbas, Ghulam" uniqKey="Abbas G" first="Ghulam" last="Abbas">Ghulam Abbas</name><affiliation><nlm:affiliation>Department of Biological Sciences and Chemistry, College of Arts and Sciences, University of Nizwa , Nizwa , Sultanate of Oman.</nlm:affiliation><wicri:noCountry code="subField">Sultanate of Oman</wicri:noCountry></affiliation></author><author><name sortKey="Adekenov, Sergazy M" sort="Adekenov, Sergazy M" uniqKey="Adekenov S" first="Sergazy M" last="Adekenov">Sergazy M. Adekenov</name><affiliation wicri:level="1"><nlm:affiliation>JSC International Research and Production Holding "Phytochemistry" , Karaganda , Republic of Kazakhstan.</nlm:affiliation><country xml:lang="fr">Kazakhstan</country><wicri:regionArea>JSC International Research and Production Holding "Phytochemistry" , Karaganda </wicri:regionArea><wicri:noRegion>Karaganda </wicri:noRegion></affiliation></author><author><name sortKey="Hussain, Wahid" sort="Hussain, Wahid" uniqKey="Hussain W" first="Wahid" last="Hussain">Wahid Hussain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Botany, GPGC Parachinar Kurram Agency Pakistan , Parachinar , Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>Department of Botany, GPGC Parachinar Kurram Agency Pakistan , Parachinar </wicri:regionArea><wicri:noRegion>Parachinar </wicri:noRegion></affiliation></author><author><name sortKey="Ali, Iftikhar" sort="Ali, Iftikhar" uniqKey="Ali I" first="Iftikhar" last="Ali">Iftikhar Ali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, Karakoram International University , Gilgit , Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>Department of Chemistry, Karakoram International University , Gilgit </wicri:regionArea><wicri:noRegion>Gilgit </wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Shandong Key Laboratory of TCM Quality Control Technology, Shandong Analysis and Test Center , Jinan , Shandong Province , P.R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Shandong Key Laboratory of TCM Quality Control Technology, Shandong Analysis and Test Center , Jinan , Shandong Province </wicri:regionArea><wicri:noRegion>Shandong Province </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31402706</idno><idno type="pmid">31402706</idno><idno type="doi">10.1080/13543776.2019.1655542</idno><idno type="wicri:Area/Main/Corpus">000271</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000271</idno><idno type="wicri:Area/Main/Curation">000271</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000271</idno><idno type="wicri:Area/Main/Exploration">000271</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).</title><author><name sortKey="Hussain, Hidayat" sort="Hussain, Hidayat" uniqKey="Hussain H" first="Hidayat" last="Hussain">Hidayat Hussain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry , Weinberg 3, D-06120 Halle (Saale) , Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry , Weinberg 3, D-06120 Halle (Saale) </wicri:regionArea><wicri:noRegion>06120 Halle (Saale) </wicri:noRegion><wicri:noRegion>06120 Halle (Saale) </wicri:noRegion><wicri:noRegion>D-06120 Halle (Saale) </wicri:noRegion></affiliation></author><author><name sortKey="Green, Ivan R" sort="Green, Ivan R" uniqKey="Green I" first="Ivan R" last="Green">Ivan R. Green</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry and Polymer Science, University of Stellenbosch , Matieland , Stellenbosch , South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Department of Chemistry and Polymer Science, University of Stellenbosch , Matieland , Stellenbosch </wicri:regionArea><wicri:noRegion>Stellenbosch </wicri:noRegion></affiliation></author><author><name sortKey="Abbas, Ghulam" sort="Abbas, Ghulam" uniqKey="Abbas G" first="Ghulam" last="Abbas">Ghulam Abbas</name><affiliation><nlm:affiliation>Department of Biological Sciences and Chemistry, College of Arts and Sciences, University of Nizwa , Nizwa , Sultanate of Oman.</nlm:affiliation><wicri:noCountry code="subField">Sultanate of Oman</wicri:noCountry></affiliation></author><author><name sortKey="Adekenov, Sergazy M" sort="Adekenov, Sergazy M" uniqKey="Adekenov S" first="Sergazy M" last="Adekenov">Sergazy M. Adekenov</name><affiliation wicri:level="1"><nlm:affiliation>JSC International Research and Production Holding "Phytochemistry" , Karaganda , Republic of Kazakhstan.</nlm:affiliation><country xml:lang="fr">Kazakhstan</country><wicri:regionArea>JSC International Research and Production Holding "Phytochemistry" , Karaganda </wicri:regionArea><wicri:noRegion>Karaganda </wicri:noRegion></affiliation></author><author><name sortKey="Hussain, Wahid" sort="Hussain, Wahid" uniqKey="Hussain W" first="Wahid" last="Hussain">Wahid Hussain</name><affiliation wicri:level="1"><nlm:affiliation>Department of Botany, GPGC Parachinar Kurram Agency Pakistan , Parachinar , Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>Department of Botany, GPGC Parachinar Kurram Agency Pakistan , Parachinar </wicri:regionArea><wicri:noRegion>Parachinar </wicri:noRegion></affiliation></author><author><name sortKey="Ali, Iftikhar" sort="Ali, Iftikhar" uniqKey="Ali I" first="Iftikhar" last="Ali">Iftikhar Ali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Chemistry, Karakoram International University , Gilgit , Pakistan.</nlm:affiliation><country xml:lang="fr">Pakistan</country><wicri:regionArea>Department of Chemistry, Karakoram International University , Gilgit </wicri:regionArea><wicri:noRegion>Gilgit </wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Shandong Key Laboratory of TCM Quality Control Technology, Shandong Analysis and Test Center , Jinan , Shandong Province , P.R. China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Shandong Key Laboratory of TCM Quality Control Technology, Shandong Analysis and Test Center , Jinan , Shandong Province </wicri:regionArea><wicri:noRegion>Shandong Province </wicri:noRegion></affiliation></author></analytic><series><title level="j">Expert opinion on therapeutic patents</title><idno type="eISSN">1744-7674</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antigens, CD (metabolism)</term><term>Diabetes Mellitus, Type 2 (drug therapy)</term><term>Diabetes Mellitus, Type 2 (enzymology)</term><term>Drug Design (MeSH)</term><term>Drug Discovery (methods)</term><term>Enzyme Inhibitors (pharmacology)</term><term>Humans (MeSH)</term><term>Hypoglycemic Agents (pharmacology)</term><term>Patents as Topic (MeSH)</term><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1 (antagonists & inhibitors)</term><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1 (metabolism)</term><term>Receptor, Insulin (metabolism)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antienzymes (pharmacologie)</term><term>Antigènes CD (métabolisme)</term><term>Brevets comme sujet (MeSH)</term><term>Conception de médicament (MeSH)</term><term>Diabète de type 2 (enzymologie)</term><term>Diabète de type 2 (traitement médicamenteux)</term><term>Découverte de médicament (méthodes)</term><term>Humains (MeSH)</term><term>Hypoglycémiants (pharmacologie)</term><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1 (antagonistes et inhibiteurs)</term><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1 (métabolisme)</term><term>Récepteur à l'insuline (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antigens, CD</term><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1</term><term>Receptor, Insulin</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="enzymologie" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>Diabetes Mellitus, Type 2</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Discovery</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antigènes CD</term><term>Protein Tyrosine Phosphatase, Non-Receptor Type 1</term><term>Récepteur à l'insuline</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Découverte de médicament</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antienzymes</term><term>Hypoglycémiants</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Enzyme Inhibitors</term><term>Hypoglycemic Agents</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète de type 2</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Design</term><term>Humans</term><term>Patents as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Brevets comme sujet</term><term>Conception de médicament</term><term>Humains</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><b>Introduction</b>: Protein tyrosine phosphatase 1B (PTP1B) inhibition has been recommended as a crucial strategy to enhance insulin sensitivity in various cells and this fact is supported by human genetic data. PTP1B inhibitors improve the sensitivity of the insulin receptor and have the ability to cure insulin resistance-related diseases. In the latter years, targeting PTP1B inhibitors is being considered an attractive target to treat T2DM and therefore libraries of PTP1B inhibitors are being suggested as potent antidiabetic drugs. <b>Areas covered</b>: This review provides an overview of published patents from January 2015 to December 2018. The review describes the effectiveness of potent PTP1B inhibitors as pharmaceutical agents to treat type 2 diabetes. <b>Expert opinion</b>: Enormous developments have been made in PTP1B drug discovery which describes progress in natural products, synthetic heterocyclic scaffolds or heterocyclic hybrid compounds. Various protocols are being followed to boost the pharmacological effects of PTP1B inhibitors. Moreover these new advancements suggest that it is possible to get small-molecule PTP1B inhibitors with the required potency and selectivity. Furthermore, future endevours via an integrated strategy of using medicinal chemistry and structural biology will hopefully result in potent and selective PTP1B inhibitors as well as safer and more effective orally available drugs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31402706</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7674</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>9</Issue><PubDate><Year>2019</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Expert opinion on therapeutic patents</Title><ISOAbbreviation>Expert Opin Ther Pat</ISOAbbreviation></Journal><ArticleTitle>Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).</ArticleTitle><Pagination><MedlinePgn>689-702</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13543776.2019.1655542</ELocationID><Abstract><AbstractText><b>Introduction</b>: Protein tyrosine phosphatase 1B (PTP1B) inhibition has been recommended as a crucial strategy to enhance insulin sensitivity in various cells and this fact is supported by human genetic data. PTP1B inhibitors improve the sensitivity of the insulin receptor and have the ability to cure insulin resistance-related diseases. In the latter years, targeting PTP1B inhibitors is being considered an attractive target to treat T2DM and therefore libraries of PTP1B inhibitors are being suggested as potent antidiabetic drugs. <b>Areas covered</b>: This review provides an overview of published patents from January 2015 to December 2018. The review describes the effectiveness of potent PTP1B inhibitors as pharmaceutical agents to treat type 2 diabetes. <b>Expert opinion</b>: Enormous developments have been made in PTP1B drug discovery which describes progress in natural products, synthetic heterocyclic scaffolds or heterocyclic hybrid compounds. Various protocols are being followed to boost the pharmacological effects of PTP1B inhibitors. Moreover these new advancements suggest that it is possible to get small-molecule PTP1B inhibitors with the required potency and selectivity. Furthermore, future endevours via an integrated strategy of using medicinal chemistry and structural biology will hopefully result in potent and selective PTP1B inhibitors as well as safer and more effective orally available drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Hidayat</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Bioorganic Chemistry, Leibniz Institute of Plant Biochemistry , Weinberg 3, D-06120 Halle (Saale) , Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Ivan R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Polymer Science, University of Stellenbosch , Matieland , Stellenbosch , South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbas</LastName><ForeName>Ghulam</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences and Chemistry, College of Arts and Sciences, University of Nizwa , Nizwa , Sultanate of Oman.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adekenov</LastName><ForeName>Sergazy M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>JSC International Research and Production Holding "Phytochemistry" , Karaganda , Republic of Kazakhstan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Wahid</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Botany, GPGC Parachinar Kurram Agency Pakistan , Parachinar , Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Iftikhar</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Chemistry, Karakoram International University , Gilgit , Pakistan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shandong Key Laboratory of TCM Quality Control Technology, Shandong Analysis and Test Center , Jinan , Shandong Province , P.R. China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Ther Pat</MedlineTA><NlmUniqueID>9516419</NlmUniqueID><ISSNLinking>1354-3776</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="C435941">INSR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D011972">Receptor, Insulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="C516607">PTPN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.3.48</RegistryNumber><NameOfSubstance UI="D054562">Protein Tyrosine Phosphatase, Non-Receptor Type 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="N">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010330" MajorTopicYN="N">Patents as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054562" MajorTopicYN="N">Protein Tyrosine Phosphatase, Non-Receptor Type 1</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011972" MajorTopicYN="N">Receptor, Insulin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PTP1B</Keyword><Keyword MajorTopicYN="N">diabetes</Keyword><Keyword MajorTopicYN="N">natural inhibitors</Keyword><Keyword MajorTopicYN="N">selectivity</Keyword><Keyword MajorTopicYN="N">synthetic inhibitor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31402706</ArticleId><ArticleId IdType="doi">10.1080/13543776.2019.1655542</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li><li>Allemagne</li><li>Kazakhstan</li><li>Pakistan</li><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Abbas, Ghulam" sort="Abbas, Ghulam" uniqKey="Abbas G" first="Ghulam" last="Abbas">Ghulam Abbas</name></noCountry><country name="Allemagne"><noRegion><name sortKey="Hussain, Hidayat" sort="Hussain, Hidayat" uniqKey="Hussain H" first="Hidayat" last="Hussain">Hidayat Hussain</name></noRegion></country><country name="Afrique du Sud"><noRegion><name sortKey="Green, Ivan R" sort="Green, Ivan R" uniqKey="Green I" first="Ivan R" last="Green">Ivan R. Green</name></noRegion></country><country name="Kazakhstan"><noRegion><name sortKey="Adekenov, Sergazy M" sort="Adekenov, Sergazy M" uniqKey="Adekenov S" first="Sergazy M" last="Adekenov">Sergazy M. Adekenov</name></noRegion></country><country name="Pakistan"><noRegion><name sortKey="Hussain, Wahid" sort="Hussain, Wahid" uniqKey="Hussain W" first="Wahid" last="Hussain">Wahid Hussain</name></noRegion><name sortKey="Ali, Iftikhar" sort="Ali, Iftikhar" uniqKey="Ali I" first="Iftikhar" last="Ali">Iftikhar Ali</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Ali, Iftikhar" sort="Ali, Iftikhar" uniqKey="Ali I" first="Iftikhar" last="Ali">Iftikhar Ali</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/BiopestPeptidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000285 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000285 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= BiopestPeptidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31402706
|texte= Protein tyrosine phosphatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31402706" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a BiopestPeptidV1
| This area was generated with Dilib version V0.6.38. |  |